Answer
Yes, upadacitinib hemihydrate treatment is associated with dose-dependent increases in total, LDL and HDL cholesterol, although the effects of these increases on cardiovascular morbidity and mortality have not been determined.
Sources for this answer
- RINVOQ 15 mg prolonged-release tabletsAbbVie Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 28Document updated
Sources checked